One of the most visible and potentially disfiguring cutaneous manifestations of tuberous sclerosis complex is the development of multiple facial angiofibromas, present in over 80% of patients. Topical rapamycin has been shown in many reports to be a safe and effective treatment for facial angiofibromas. In February 2012 we reported the results of a pilot study of four patients undertaken at a paediatric tertiary hospital in Australia. Since then, we have continued to refine the optimal formulation and concentration of topical rapamycin and expanded our selection of patients. We present an update on our current cohort of treated patients, discuss the optimal formulation of topical rapamycin and include a literature review on all published cases to date. Although topical rapamycin is not a curative treatment, we have demonstrated that its early institution significantly reduces both the vascularity and palpability of angiofibromas and prevents their progression with age. It is well tolerated and now a cost effective option.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ajd.12125 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tuberous sclerosis: a survey in the canton of Vaud, Switzerland.
Front Med (Lausanne)
December 2024
Department of Medicine, Service of Nephrology, Fribourg State Hospital, Fribourg, Switzerland.
Aim Of The Study: Tuberous sclerosis complex (TSC) is a genetic and multisystemic disorder that affects between 1/6'000 and 1/10'000 of newborns. Clinical criteria and/or genetic analysis establish the diagnosis. The mechanistic target of rapamycin (mTOR) inhibitors everolimus or sirolimus reduce the severity of several TSC-related clinical traits.
View Article and Find Full Text PDFTargeting mechanistic target of rapamycin complex 2 attenuates immunopathology in Systemic Lupus Erythematosus.
Rheumatology (Oxford)
December 2024
Division of Rheumatology, Department of Medicine, Mayo Clinic Rochester, MN, USA.
Objective: We aim to explore the role of mechanistic target of rapamycin complex (mTORC) 2 in systemic lupus erythematosus (SLE) development, the in vivo regulation of mTORC2 by type I interferon (IFN) signaling in autoimmunity, and to use mTORC2 targeting therapy to ameliorate lupus-like symptoms in an in vivo lupus mouse model and an in vitro coculture model using human PBMCs.
Method: We first induced lupus-like disease in T cell specific Rictor, a key component of mTORC2, deficient mice by topical application of imiquimod (IMQ) and monitored disease development. Next, we investigated the changes of mTORC2 signaling and immunological phenotypes in type I IFNAR deficient Lpr mice.
Selective small molecule inhibitors for hidradenitis suppurativa: Today and tomorrow.
J Am Acad Dermatol
December 2024
Department of Dermatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, University of Minnesota, Minneapolis, Minnesota; Departments of Medicine and Dermatology, Minneapolis VA Health Care System, Minneapolis, Minnesota. Electronic address:
Hidradenitis suppurativa (HS) is an autoinflammatory condition characterized by abscesses, inflammatory nodules, and tunnels in intertriginous sites of the body. The pathogenesis of HS involves follicular occlusion in combination with environmental, genetic, hormonal, and metabolic factors. HS lesions are characterized by an influx of neutrophils, histiocytes, B and T cells, and upregulation of proinflammatory cytokines such as tumor necrosis factor-α, interleukin-1, interleukin-17, and interferons.
View Article and Find Full Text PDFTrial protocol for SiroSkin: a randomised double-blind placebo-controlled trial of topical sirolimus in chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients.
Trials
November 2024
Frazer Institute, The University of Queensland, Experimental Dermatology Group, Brisbane, Australia.
Article Synopsis
- Keratinocyte carcinomas, like basal and squamous cell carcinomas, are common and serious issues for solid organ transplant recipients, necessitating early detection and effective treatment strategies.
- A Phase III clinical trial, called the SiroSkin trial, will assess the effectiveness of topical sirolimus in reducing skin cancer incidence among these patients compared to a placebo, involving 146 participants over 24 weeks of treatment and 18 months of follow-up.
- The trial's results aim to enhance management approaches for skin cancers in solid organ transplant recipients and gather evidence on the cost-effectiveness of using topical sirolimus.
Q-switched alexandrite laser combined with topical rapamycin in 22 patients with laser-resistant facial café-au-lait macules.
J Eur Acad Dermatol Venereol
November 2024
Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!